GlassScriptPhysician profile
Adriane D Burns
NPI 1730794694
$978.41
in general payments reported to CMS, 2019-2025
15 companies · $21.33 in 2025
The $21.33 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $22.83 · 2023: $649 · 2024: $169 · 2025: $21.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.95 | 2021-2024 | Verquvo |
| Cvrx, INC. | $158.01 | 2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $87.01 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $63.54 | 2021 | |
| Amgen INC. | $57.60 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $47.54 | 2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.20 | 2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $38.69 | 2024 | Inpefa |
| Pfizer INC. | $30.18 | 2023 | |
| Boston Scientific Corporation | $22.83 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.10 | 2023 | Arcalyst |
| Abbvie INC. | $21.33 | 2025 | |
| Daiichi Sankyo INC. | $17.74 | 2023 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $17.62 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $17.07 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriane Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.